KIORA PHARMACEUTICALS, INC. Operating Lease, Right-of-Use Asset, Amortization Expense
KIORA PHARMACEUTICALS, INC. (KPRX) reported Operating Lease, Right-of-Use Asset, Amortization Expense of $200.00 thousand for the 12-month period ending 2025-12-31, per its 10-K filed 2026-03-25.
Financial Statements › Cash Flow › Operating Activities
us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense · last filed 2026-03-25
- KIORA PHARMACEUTICALS, INC. operating lease, right-of-use asset, amortization expense for the quarter ending 2021-09-30 was $54.84K.
- KIORA PHARMACEUTICALS, INC. operating lease, right-of-use asset, amortization expense for the quarter ending 2021-06-30 was $55.19K.
- KIORA PHARMACEUTICALS, INC. operating lease, right-of-use asset, amortization expense for the quarter ending 2021-03-31 was $50.85K.
- KIORA PHARMACEUTICALS, INC. operating lease, right-of-use asset, amortization expense for fiscal 2025 was $200.00K, a 100.00% increase from fiscal 2024.
- KIORA PHARMACEUTICALS, INC. operating lease, right-of-use asset, amortization expense for fiscal 2024 was $100.00K, a 50.00% decline from fiscal 2023.
- KIORA PHARMACEUTICALS, INC. operating lease, right-of-use asset, amortization expense for fiscal 2023 was $200.00K, a 100.00% increase from fiscal 2022.
- KIORA PHARMACEUTICALS, INC. operating lease, right-of-use asset, amortization expense for fiscal 2022 was $100.00K, a 53.49% decline from fiscal 2021.
| Period end | Operating Lease, Right-of-Use Asset, Amortization Expense 3 month | Operating Lease, Right-of-Use Asset, Amortization Expense 6 month | Operating Lease, Right-of-Use Asset, Amortization Expense 9 month | Operating Lease, Right-of-Use Asset, Amortization Expense 12 month |
|---|---|---|---|---|
| 2025-12-31 | $200.00K 10-K · filed 2026-03-25 | |||
| 2024-12-31 | $100.00K 10-K · filed 2026-03-25 | |||
| 2023-12-31 | $200.00K 10-K · filed 2025-03-25 | |||
| 2022-12-31 | $100.00K 10-K · filed 2024-03-25 | |||
| 2021-12-31 | $215.00K 10-K/A · filed 2022-07-07 | |||
| 2021-09-30 | $54.84K 10-Q · filed 2021-11-15 | $110.03K derived: sum of 2 quarters · filed 2021-11-15 | $160.88K derived: sum of 3 quarters · filed 2021-11-15 | |
| 2021-06-30 | $55.19K 10-Q · filed 2021-08-12 | $106.04K derived: sum of 2 quarters · filed 2021-08-12 | ||
| 2021-03-31 | $50.85K 10-Q · filed 2021-05-12 | |||
| 2020-12-31 | $174.00K 10-K · filed 2021-03-25 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Scienture Holdings, Inc. (SCNX) | United States | $0.012B | -0.38 |
| Phio Pharmaceuticals Corp. (PHIO) | United States | $0.012B | -0.92 |
| ADIAL PHARMACEUTICALS, INC. (ADIL) | United States | $0.012B | |
| Dare Bioscience, Inc. (DARE) | United States | $0.011B | |
| BIOVIE INC. (BIVI) | United States | $0.012B | |
| Aspire Biopharma Holdings, Inc. (ASBP) | United States | $0.012B | -0.60 |
| Tempest Therapeutics, Inc. (TPST) | United States | $0.013B | |
| Moleculin Biotech, Inc. (MBRX) | United States | $0.011B | |
| MetaVia Inc. (MTVA) | United States | $0.011B | -0.65 |
| KALA BIO, Inc. (KALA) | United States | $0.011B | -3.33 |